Bellevue Group AG
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Bellevue Group AG reported 155 stock positions worth $4.2 billion. Its top holding was Vertex Pharmaceuticals (VRTX) at 7.2% of the portfolio, followed by Argenx SE - ADR (ARGX, 5.4%) and Regeneron Pharmaceuticals (REGN, 5.1%). Compared with Q4 2025, it opened 19 new positions, sold out of 40, added to 34 and reduced 87. The biggest buy was Regeneron Pharmaceuticals (REGN, shares +1901%) and the biggest sale Neurocrine Biosciences (NBIX, shares −100%).
- Most Recent 13F
- Q2 2026
- Location
- ZURICH, V8
- CIK
- 0001674546
- Portfolio Value
- $4.2B (Q1 2026)
- SEC Filing
- 0001104659-26-061375 ↗ filed May 15, 2026
Holdings Value
Holdings 155 stocks · $4.2B
| VRTX Vertex Pharmaceuticals Inc. | 7.25% | 681,908 | $304.5M | Add +0.1% |
| ARGX Argenx SE - ADR | 5.44% | 313,000 | $228.6M | Reduce -32.2% |
| REGN Regeneron Pharmaceuticals | 5.12% | 278,674 | $215.3M | Add +1900.8% |
| SRRK Scholar Rock Holding Corp. | 4.19% | 3,584,573 | $176.2M | Reduce -11.6% |
| GILD Gilead Sciences Inc. | 3.88% | 1,169,879 | $163.0M | Add +2117.7% |
| RVMD Revolution Medicines Inc. | 3.57% | 1,544,456 | $150.2M | Reduce -69.2% |
| IONS Ionis Pharmaceuticals Inc. | 3.25% | 1,818,665 | $136.6M | Reduce -62.1% |
| ISRG Intuitive Surgical Inc. | 3.14% | 286,654 | $132.1M | Reduce -11.0% |
| VRDN Viridian Therapeutics Inc. | 3.13% | 6,726,144 | $131.6M | Add +54.3% |
| KRYS Krystal Biotech Inc. | 2.96% | 481,785 | $124.5M | Add +17.4% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.84% | 3,280,000 | $119.1M | Add +81088.1% |
| ABT Abbott Laboratories | 2.81% | 1,151,635 | $118.2M | Reduce -12.6% |
| NUVL Nuvalent Inc. Class A | 2.57% | 1,053,268 | $107.9M | Add +1.5% |
| AMGN Amgen Inc. | 2.47% | 295,358 | $103.9M | Add +1497.5% |
| BSX Boston Scientific Corp. | 2.19% | 1,466,894 | $92.0M | Reduce -5.9% |
| ELVN Enliven Therapeutics Inc. | 2.17% | 2,320,867 | $91.0M | New |
| IMCR Immunocore Holdings PLC-ADR | 2.01% | 2,796,803 | $84.3M | No change |
| MDT Medtronic PLC | 1.97% | 957,329 | $83.0M | Add +24.9% |
| ALNY Alnylam Pharmaceuticals Inc. | 1.85% | 234,543 | $77.6M | Reduce -47.4% |
| RLAY Relay Therapeutics Inc. | 1.85% | 7,795,242 | $77.6M | Reduce -6.6% |
| SYK Stryker Corp. | 1.70% | 217,237 | $71.4M | Reduce -39.8% |
| PCVX Vaxcyte Inc. | 1.65% | 1,190,697 | $69.2M | New |
| VERA Vera Therapeutics Inc. | 1.64% | 1,710,771 | $68.8M | Add +0.7% |
| EW Edwards Lifesciences Corp. | 1.60% | 839,451 | $67.2M | Reduce -19.5% |
| DMRA Damora Therapeutics Inc. | 1.42% | 2,298,000 | $59.5M | New |
| TNGX Tango Therapeutics Inc. | 1.19% | 2,400,000 | $50.2M | Reduce -38.9% |
| IDXX Idexx Laboratories Inc. | 1.19% | 89,131 | $50.1M | Reduce -5.7% |
| RARE Ultragenyx Pharmaceutical Inc. | 1.19% | 2,380,000 | $49.9M | Add +92148.1% |
| DXCM Dexcom Inc. | 1.18% | 788,766 | $49.5M | Reduce -6.9% |
| JBIO Jade Biosciences Inc. | 1.17% | 3,501,502 | $49.2M | Add +4.8% |
| EWTX Edgewise Therapeutics Inc. | 1.15% | 1,528,518 | $48.1M | No change |
| UNH Unitedhealth Group Inc. | 0.95% | 148,203 | $40.1M | Reduce -15.4% |
| DHR Danaher Corp. | 0.91% | 202,164 | $38.3M | Add +3.9% |
| CLDX Celldex Therapeutics Inc. | 0.91% | 1,200,000 | $38.1M | Reduce -66.8% |
| RMD Resmed Inc. | 0.85% | 159,346 | $35.8M | Reduce -1.2% |
| PODD Insulet Corp. | 0.82% | 163,656 | $34.3M | Reduce -12.3% |
| TMO Thermo Fisher Scientific Inc. | 0.75% | 64,412 | $31.7M | Reduce -1.0% |
| LLY Eli Lilly & Co. | 0.74% | 33,932 | $31.2M | Reduce -0.2% |
| GEHC GE Healthcare Technology | 0.71% | 416,887 | $29.7M | Reduce -1.8% |
| IRON Disc Medicine Inc. | 0.70% | 459,314 | $29.4M | New |
| JNJ Johnson & Johnson | 0.69% | 119,102 | $29.1M | Reduce -6.1% |
| ANNX Annexon Inc. | 0.68% | 5,157,290 | $28.6M | No change |
| CI The Cigna Group | 0.62% | 98,263 | $26.2M | Reduce -10.7% |
| ORKA Oruka Therapeutics Inc. | 0.59% | 507,008 | $24.9M | New |
| MRK Merck & Co. Inc. | 0.59% | 206,591 | $24.9M | Add +124.3% |
| ALGN Align Technology Inc. | 0.57% | 139,680 | $23.9M | Reduce -1.3% |
| STE Steris PLC | 0.53% | 99,878 | $22.1M | Reduce -1.8% |
| GMED Globus Medical Inc. Class A | 0.51% | 247,261 | $21.3M | Reduce -5.9% |
| GLUE Monte Rosa Therapeutics Inc. | 0.49% | 1,250,000 | $20.6M | New |
| ABBV Abbvie Inc. | 0.48% | 93,567 | $20.3M | Reduce -30.6% |
| COO The Cooper Cos Inc. | 0.46% | 272,184 | $19.5M | Reduce -6.8% |
| MCK McKesson Corp. | 0.46% | 22,352 | $19.3M | Reduce -10.9% |
| BDX Becton Dickinson and Co. | 0.46% | 121,887 | $19.2M | Reduce -54.1% |
| HCA HCA Healthcare Inc. | 0.43% | 37,765 | $17.9M | Reduce -14.0% |
| GKOS Glaukos Corp. | 0.37% | 145,703 | $15.7M | Reduce -44.4% |
| ELV Elevance Health Inc. | 0.37% | 52,518 | $15.4M | Reduce -24.6% |
| ZBH Zimmer Biomet Holdings Inc. | 0.33% | 155,571 | $14.1M | Reduce -34.8% |
| PRCT Procept Biorobotics Corp. | 0.30% | 502,286 | $12.6M | Reduce -2.5% |
| LIVN Livanova PLC | 0.28% | 186,185 | $11.8M | New |
| HUM Humana Inc. | 0.27% | 64,498 | $11.2M | Reduce -11.7% |
| TMDX Transmedics Group Inc. | 0.24% | 101,139 | $10.1M | Add +3.3% |
| VEEV Veeva Systems Inc. Class A | 0.24% | 56,517 | $9.9M | Reduce -29.8% |
| CNC Centene Corp. | 0.20% | 261,066 | $8.5M | Reduce -4.6% |
| TEVA Teva Pharmaceutical-SP ADR | 0.18% | 250,082 | $7.5M | Reduce -23.7% |
| THC Tenet Healthcare Corp. | 0.17% | 38,269 | $7.2M | Reduce -4.9% |
| TXG 10X Genomics Inc. Class A | 0.17% | 329,492 | $7.0M | Add +2.3% |
| CVS CVS Health Corp. | 0.15% | 89,363 | $6.4M | Reduce -18.1% |
| NTRA Natera Inc. | 0.15% | 31,694 | $6.3M | Reduce -43.4% |
| WAY Waystar Holding Corp. | 0.15% | 256,139 | $6.2M | Add +6.0% |
| MDLN Medline Inc. Class A | 0.14% | 136,635 | $6.1M | Add +16.1% |
| INSP Inspire Medical Systems Inc. | 0.12% | 99,735 | $5.1M | Reduce -1.0% |
| PRVA Privia Health Group Inc. | 0.11% | 226,703 | $4.7M | Reduce -49.4% |
| PEN Penumbra Inc. | 0.10% | 12,267 | $4.0M | Reduce -90.9% |
| RNA Atrium Therapeutics Inc. | 0.08% | 263,096 | $3.5M | New |
| PFE Pfizer Inc. | 0.07% | 107,635 | $3.0M | Add +89.3% |
| ILMN Illumina Inc. | 0.06% | 20,223 | $2.5M | Reduce -11.8% |
| KMTS Kestra Medical Technologies | 0.05% | 115,590 | $2.3M | Reduce -0.1% |
| OMDA Omada Health Inc. | 0.05% | 157,938 | $2.0M | Reduce -11.2% |
| BBIO Bridgebio Pharma Inc. | 0.04% | 25,377 | $1.9M | Add +5.3% |
| BNTX Biontech SE-ADR | 0.04% | 20,851 | $1.9M | Reduce -52.4% |
| RPRX Royalty Pharma PLC Class A | 0.04% | 38,296 | $1.8M | Add +190.1% |
| SPY SS SPDR S&P 500 ETF Trust-US | 0.04% | 2,700 | $1.8M | Reduce -12.9% |
| INSM Insmed Inc. | 0.04% | 10,034 | $1.6M | Reduce -27.9% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.04% | 3,040 | $1.6M | Add +5.4% |
| MASI Masimo Corp. | 0.04% | 8,753 | $1.6M | Reduce -91.0% |
| PTGX Protagonist Therapeutics Inc. | 0.04% | 14,447 | $1.5M | Reduce -12.7% |
| UTHR United Therapeutics Corp. | 0.03% | 2,077 | $1.2M | Reduce -46.7% |
| ONC Beone Medicines Ltd.-ADR | 0.03% | 3,812 | $1.1M | Add +101.7% |
| PHR Phreesia Inc. | 0.03% | 130,992 | $1.1M | Reduce -28.5% |
| ADPT Adaptive Biotechnologies | 0.03% | 76,181 | $1.1M | Reduce -74.4% |
| BMY Bristol-Myers Squibb Co. | 0.02% | 17,038 | $1.0M | Reduce -74.6% |
| EHC Encompass Health Corp. | 0.02% | 9,829 | $951K | Reduce -48.5% |
| NAMS Newamsterdam Pharma Co. NV | 0.02% | 27,661 | $885K | Reduce -23.9% |
| AAPL Apple Inc. | 0.02% | 3,320 | $843K | No change |
| BLLN Billiontoone Inc. Class A | 0.02% | 10,554 | $833K | Reduce -0.3% |
| MLYS Mineralys Therapeutics Inc. | 0.02% | 29,374 | $796K | Add +48.2% |
| EQNR Equinor ASA-Spon ADR | 0.02% | 17,573 | $742K | New |
| XOM Exxon Mobil Corp. | 0.02% | 4,370 | $741K | New |
| BP BP PLC-Spons ADR | 0.02% | 15,644 | $735K | New |
| SHEL Shell PLC-ADR | 0.02% | 7,844 | $729K | New |
Portfolio Sells Q4 2025 → Q1 2026
| NBIX Neurocrine Biosciences Inc. | Reduce -99.7% | 0.01% | −4.56 |
| RVMD Revolution Medicines Inc. | Reduce -69.2% | 3.57% | −3.98 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -62.1% | 3.25% | −3.95 |
| RNAM Avidity Biosciences Inc. | Sold out | 0.00% | −3.60 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −2.90 |
| ARGX Argenx SE - ADR | Reduce -32.2% | 5.44% | −1.92 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -47.4% | 1.85% | −1.51 |
| CLDX Celldex Therapeutics Inc. | Reduce -66.8% | 0.91% | −0.96 |
| SYK Stryker Corp. | Reduce -39.8% | 1.70% | −0.70 |
| PEN Penumbra Inc. | Reduce -90.9% | 0.10% | −0.70 |
| MAZE Maze Therapeutics Inc. | Sold out | 0.00% | −0.70 |
| BSX Boston Scientific Corp. | Reduce -5.9% | 2.19% | −0.63 |
| BDX Becton Dickinson and Co. | Reduce -54.1% | 0.46% | −0.52 |
| WVE Wave Life Sciences Ltd. | Reduce -99.7% | 0.00% | −0.48 |
| ABT Abbott Laboratories | Reduce -12.6% | 2.81% | −0.31 |
| ISRG Intuitive Surgical Inc. | Reduce -11.0% | 3.14% | −0.31 |
| MASI Masimo Corp. | Reduce -91.0% | 0.04% | −0.20 |
| PODD Insulet Corp. | Reduce -12.3% | 0.82% | −0.19 |
| GKOS Glaukos Corp. | Reduce -44.4% | 0.37% | −0.19 |
| GPCR Structure Therapeutics Inc. | Reduce -95.3% | 0.01% | −0.18 |
| IQV Iqvia Holdings Inc. | Reduce -98.2% | 0.00% | −0.17 |
| CDNA Caredx Inc. | Sold out | 0.00% | −0.15 |
| MOH Molina Healthcare Inc. | Sold out | 0.00% | −0.15 |
| UNH Unitedhealth Group Inc. | Reduce -15.4% | 0.95% | −0.14 |
| VEEV Veeva Systems Inc. Class A | Reduce -29.8% | 0.24% | −0.10 |
| ABBV Abbvie Inc. | Reduce -30.6% | 0.48% | −0.10 |
| ELV Elevance Health Inc. | Reduce -24.6% | 0.37% | −0.10 |
| ASND Ascendis Pharma A/S | Reduce -97.8% | 0.00% | −0.10 |
| NTRA Natera Inc. | Reduce -43.4% | 0.15% | −0.09 |
| PRVA Privia Health Group Inc. | Reduce -49.4% | 0.11% | −0.09 |
| HUM Humana Inc. | Reduce -11.7% | 0.27% | −0.09 |
| EW Edwards Lifesciences Corp. | Reduce -19.5% | 1.60% | −0.09 |
| ICLR Icon PLC | Sold out | 0.00% | −0.08 |
| AXSM Axsome Therapeutics Inc. | Reduce -88.5% | 0.01% | −0.08 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −0.07 |
| ZBH Zimmer Biomet Holdings Inc. | Reduce -34.8% | 0.33% | −0.07 |
| ADPT Adaptive Biotechnologies | Reduce -74.4% | 0.03% | −0.07 |
| BTSG Brightspring Health Services | Sold out | 0.00% | −0.07 |
| NEO Neogenomics Inc. | Sold out | 0.00% | −0.06 |
| AVTR Avantor Inc. | Sold out | 0.00% | −0.06 |
| BEAM Beam Therapeutics Inc. | Sold out | 0.00% | −0.06 |
| INSP Inspire Medical Systems Inc. | Reduce -1.0% | 0.12% | −0.05 |
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −0.05 |
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.04 |
| BMY Bristol-Myers Squibb Co. | Reduce -74.6% | 0.02% | −0.04 |
| BNTX Biontech SE-ADR | Reduce -52.4% | 0.04% | −0.03 |
| BKD Brookdale Senior Living Inc. | Sold out | 0.00% | −0.03 |
| SIBN Si-Bone Inc. | Sold out | 0.00% | −0.03 |
| PHR Phreesia Inc. | Reduce -28.5% | 0.03% | −0.03 |
Portfolio Buys Q4 2025 → Q1 2026
| REGN Regeneron Pharmaceuticals | Add +1900.8% | 5.12% | +4.92 |
| GILD Gilead Sciences Inc. | Add +2117.7% | 3.88% | +3.76 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +81088.1% | 2.84% | +2.83 |
| AMGN Amgen Inc. | Add +1497.5% | 2.47% | +2.36 |
| ELVN Enliven Therapeutics Inc. | New | 2.17% | +2.17 |
| PCVX Vaxcyte Inc. | New | 1.65% | +1.65 |
| DMRA Damora Therapeutics Inc. | New | 1.42% | +1.42 |
| VRTX Vertex Pharmaceuticals Inc. | Add +0.1% | 7.25% | +1.39 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +92148.1% | 1.19% | +1.19 |
| KRYS Krystal Biotech Inc. | Add +17.4% | 2.96% | +1.04 |
| IRON Disc Medicine Inc. | New | 0.70% | +0.70 |
| ORKA Oruka Therapeutics Inc. | New | 0.59% | +0.59 |
| NUVL Nuvalent Inc. Class A | Add +1.5% | 2.57% | +0.59 |
| MDT Medtronic PLC | Add +24.9% | 1.97% | +0.58 |
| VRDN Viridian Therapeutics Inc. | Add +54.3% | 3.13% | +0.56 |
| GLUE Monte Rosa Therapeutics Inc. | New | 0.49% | +0.49 |
| MRK Merck & Co. Inc. | Add +124.3% | 0.59% | +0.41 |
| LIVN Livanova PLC | New | 0.28% | +0.28 |
| JBIO Jade Biosciences Inc. | Add +4.8% | 1.17% | +0.19 |
| RNA Atrium Therapeutics Inc. | New | 0.08% | +0.08 |
| DHR Danaher Corp. | Add +3.9% | 0.91% | +0.07 |
| TXG 10X Genomics Inc. Class A | Add +2.3% | 0.17% | +0.07 |
| MDLN Medline Inc. Class A | Add +16.1% | 0.14% | +0.05 |
| PFE Pfizer Inc. | Add +89.3% | 0.07% | +0.05 |
| RPRX Royalty Pharma PLC Class A | Add +190.1% | 0.04% | +0.03 |
| EQNR Equinor ASA-Spon ADR | New | 0.02% | +0.02 |
| XOM Exxon Mobil Corp. | New | 0.02% | +0.02 |
| BP BP PLC-Spons ADR | New | 0.02% | +0.02 |
| SHEL Shell PLC-ADR | New | 0.02% | +0.02 |
| ONC Beone Medicines Ltd.-ADR | Add +101.7% | 0.03% | +0.02 |
| TMDX Transmedics Group Inc. | Add +3.3% | 0.24% | +0.01 |
| PRAX Praxis Precision Medicines I | New | 0.01% | +0.01 |
| AGMB Agomab Therapeutics NV | New | 0.01% | +0.01 |
| BBIO Bridgebio Pharma Inc. | Add +5.3% | 0.04% | +0.01 |
| COR Cencora Inc. | Add +229.4% | 0.01% | +0.01 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 0.01% | +0.01 |
| VERA Vera Therapeutics Inc. | Add +0.7% | 1.64% | +0.01 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +5.4% | 0.04% | +0.01 |
| DNLI Denali Therapeutics Inc. | Add +148.9% | 0.01% | +0.01 |
| HALO Halozyme Therapeutics Inc. | New | 0.01% | +0.01 |
| MLYS Mineralys Therapeutics Inc. | Add +48.2% | 0.02% | +0.01 |
| BIIB Biogen Inc. | Add +2.5% | 0.02% | +0.00 |
| OLMA Olema Pharmaceuticals Inc. | Add +321.4% | 0.01% | +0.00 |
| ALKS Alkermes PLC | Add +34.5% | 0.01% | +0.00 |
| CRSP Crispr Therapeutics AG | Add +166.8% | 0.01% | +0.00 |
| TVTX Travere Therapeutics Inc. | Add +132.5% | 0.01% | +0.00 |
| ABVX Abivax SA-ADR | New | 0.00% | +0.00 |
| SMMT Summit Therapeutics Inc. | Add +11.2% | 0.01% | +0.00 |
| BBOT Bridgebio Oncology Therapeut | New | 0.00% | +0.00 |
| A Agilent Technologies Inc. | Add +89.7% | 0.00% | +0.00 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 148 | $4.8B | AMGN, VRTX, ARGX, GILD, RVMD |
| Q1 2026 | 155 | $4.2B | VRTX, ARGX, REGN, SRRK, GILD |
| Q4 2025 | 176 | $5.3B | RVMD, ARGX, IONS, VRTX, NBIX |
| Q3 2025 | 148 | $4.8B | IONS, ARGX, RVMD, NBIX, ALNY |
| Q2 2025 | 142 | $4.5B | ARGX, IONS, NBIX, ALNY, ABT |
| Q1 2025 | 148 | $4.5B | ARGX, IONS, SYK, ISRG, ALNY |
| Q4 2024 | 160 | $5.2B | ARGX, IONS, NBIX, ISRG, ITCI |
| Q3 2024 | 162 | $6.2B | ARGX, IONS, VRTX, ISRG, ALNY |
| Q2 2024 | 166 | $6.2B | IONS, ARGX, VRTX, NBIX, ISRG |
| Q1 2024 | 169 | $6.6B | IONS, ARGX, NBIX, VRTX, ISRG |